Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Dementia Medicines Taskforce

- PMLiVE

UK and US agree on landmark pharma pricing tariff deal

US tariffs on UK-produced pharmaceuticals will remain at zero for three years

- PMLiVE

ViiV Healthcare receives NICE recommendation for HIV prevention therapy

The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

- PMLiVE

Lilly and WHO Foundation partner to support global dementia action plan

The partnership will provide financial support and strengthen early detection and intervention efforts

- PMLiVE

New National Commission launched to strengthen AI regulation

The Commission will unite healthcare leaders, regulators and technology experts to shape future AI governance

- PMLiVE

Lilly launches global Alzheimer’s campaign with Julianne Moore

The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health

- PMLiVE

NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

More than 11,000 people are diagnosed with head and neck cancers every year in England

- PMLiVE

NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

- PMLiVE

UK government publishes 10 Year Health Plan for England to ‘reinvent’ NHS

The plan’s three overarching themes are hospital to community, analogue to digital and sickness to prevention

- PMLiVE

BioNTech announces £1bn UK investment to boost regional R&D presence

The UK government has also agreed to award the company a grant of up to £129m

- PMLiVE

NHS patients to access Theramex’s endometriosis pill following NICE recommendation

The once-a-day drug has been recommended for patients with a history of previous medical or surgical treatment

- PMLiVE

UK government’s AMR study highlights importance of appropriate antibiotic use

The UKHSA found that some bacteria are already becoming resistant to ceftazidime/avibactam

- PMLiVE

NHS programme to give melanoma patients fast-track access to skin cancer vaccine

The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links